PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina
- PMID: 35610400
- DOI: 10.1007/s10549-022-06620-5
PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina
Abstract
Purpose: PALB2 variants have been scarcely described in Argentinian and Latin-American reports. In this study, we describe molecular and clinical characteristics of PALB2 mutations found in multi-gene panels (MP) from breast-ovarian cancer (BOC) families in different institutions from Argentina.
Methods: We retrospectively identified PALB2 pathogenic (PV) and likely pathogenic (LPV) variants from a cohort of 1905 MP results, provided by one local lab (Heritas) and SITHER (Hereditary Tumor Information System) public database. All patients met hereditary BOC clinical criteria for testing, according to current guidelines.
Results: The frequency of PALB2 mutations is 2.78% (53/1905). Forty-eight (90.5%) are PV and five (9.5%) are LPV. Most of the 18 different mutations (89%) are nonsense and frameshift types and 2 variants are novel. One high-rate recurrent PV (Y551*) is present in 43% (23/53) of the unrelated index cases. From the 53 affected carriers, 94% have BC diagnosis with 14% of bilateral cases. BC phenotype is mainly invasive ductal (78%) with 62% of hormone-receptor positive and 22% of triple negative tumors. Self-reported ethnic background of the cohort is West European (66%) and native Latin-American (20%) which is representative of Buenos Aires and other big urban areas of the country.
Conclusion: This is the first report describing molecular and clinical characteristics of PALB2 carriers in Argentina. Frequency of PALB2 PV in Argentinian HBOC families is higher than in other reported populations. Y551* is a recurrent mutation that seems to be responsible for almost 50% of PALB2 cases.
Keywords: Argentina; Breast-ovarian cancer; Germline mutations; Multi-gene panel; PALB2; Recurrent mutation.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
PALB2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients.Sci Rep. 2023 May 11;13(1):7666. doi: 10.1038/s41598-023-34693-9. Sci Rep. 2023. PMID: 37169825 Free PMC article.
-
Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.Breast Cancer Res Treat. 2019 Dec;178(3):629-636. doi: 10.1007/s10549-019-05411-9. Epub 2019 Aug 24. Breast Cancer Res Treat. 2019. PMID: 31446535
-
Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.Breast Cancer Res Treat. 2020 Feb;179(3):605-614. doi: 10.1007/s10549-019-05483-7. Epub 2019 Nov 25. Breast Cancer Res Treat. 2020. PMID: 31768816
-
Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.Breast Cancer Res Treat. 2020 Jul;182(2):465-476. doi: 10.1007/s10549-020-05710-6. Epub 2020 Jun 2. Breast Cancer Res Treat. 2020. PMID: 32488392
-
Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Breast Cancer Res Treat. 2016 Dec;160(3):393-410. doi: 10.1007/s10549-016-4003-9. Epub 2016 Oct 12. Breast Cancer Res Treat. 2016. PMID: 27734215 Review.
Cited by
-
Two recurrent pathogenic/likely pathogenic variants in PALB2 account for half of PALB2 positive families in Slovenia.Hum Genomics. 2024 Dec 18;18(1):137. doi: 10.1186/s40246-024-00706-5. Hum Genomics. 2024. PMID: 39696405 Free PMC article. No abstract available.
-
Clinicopathological Features and Oncological Outcomes of Germline Partner and Localizer of Breast Cancer 2-Mutated Breast Cancer in Korea.J Breast Cancer. 2024 Dec;27(6):372-382. doi: 10.4048/jbc.2024.0146. J Breast Cancer. 2024. PMID: 39761944 Free PMC article.
-
Overview of the Genetic Causes of Hereditary Breast and Ovarian Cancer Syndrome in a Large French Patient Cohort.Cancers (Basel). 2023 Jun 29;15(13):3420. doi: 10.3390/cancers15133420. Cancers (Basel). 2023. PMID: 37444530 Free PMC article.
-
Contribution of large genomic rearrangements in BRCA1/2 genes and CHEK2 1100delC allele variant to the development of breast/ovarian cancer in Argentinian population.Breast Cancer Res Treat. 2025 Apr;210(2):385-391. doi: 10.1007/s10549-024-07576-4. Epub 2024 Dec 20. Breast Cancer Res Treat. 2025. PMID: 39704897
References
-
- Antoniou AC, Casadei S, Heikkinen T et al (2014) Breast-cancer risk in families with mutations in PALB2. N Engl J Med 371(6):497–506. https://doi.org/10.1056/NEJMoa1400382 - DOI - PubMed - PMC
-
- Yang X, Leslie G, Doroszuk A et al (2020) Cancer risks associated with Germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 38(7):674–685. https://doi.org/10.1200/JCO.19.01907 - DOI - PubMed
-
- Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J et al (2021) Breast cancer risk genes—association analysis in more than 113,000 women. N Engl J Med 384(5):428–439. https://doi.org/10.1056/NEJMoa1913948 - DOI
-
- Hu C, Hart SN, Gnanaolivu R et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384(5):440–451. https://doi.org/10.1056/NEJMoa2005936 - DOI - PubMed - PMC
-
- Kurian AW, Hughes E, Handorf EA, Gutin A, Allen B, Hartman AR, Hall MJ (2017) Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women. JCO Precis Oncol 1:1–12. https://doi.org/10.1200/PO.16.00066 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous